Over the past few years, a number of advanced vaccines targeting a myriad of disease indications have received approval from various regulatory authorities. Post the onset of COVID-19, there has been a surge in the demand for viral vaccines. In fact, it is estimated that more than 4.5 billion people, across the globe, have received at least a single dose of COVID-19 vaccine. In other words, around 60% of the global population has been vaccinated against COVID-19. However, as the global population continues to rise, the demand for such vaccines is likely to be there in the foreseen future as well. Taking into consideration the prevalent trends, the global vaccines market is anticipated to be worth around USD 100 billion in 2025. Amidst the recent initiatives in this context, several viral vaccine media developers have established various partnerships for the clinical and commercial manufacturing of viral vaccines.
Vaccine manufacturing is a highly regulated and challenging process; specifically, the production of viral components or whole viruses further adds to the complexity. Additionally, it is paramount for vaccine cultures to be devoid of any contamination and be highly effective. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing. As a matter of fact, the recent surge in vaccine demand amidst the COVID-19 pandemic has served to facilitate a strong case for organizations to opt such media for the development and manufacturing of large quantities of vaccines. In fact, players engaged in this domain have shifted their focus towards serum free and animal component free media to carry out vaccine manufacturing owing to the various benefits offered by these media formulations, including low contamination rate. Given that the demand for viral vaccine is indubitably rising, the corresponding opportunity for viral vaccine cell culture media is expected to witness steady growth, over the next decade.
An analysis of the recent developments and initiatives within the viral vaccine cell culture media industry, highlighting information on several partnerships and collaborations and expansion initiatives that have taken place in this domain, during the period 2015-2021. An in-depth analysis of more than 130 vaccine developers and 50 vaccine contract manufacturers that are likely to partner with viral vaccine cell culture media providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field) , pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other vaccine development and manufacturing related capabilities.